A Qualitative Study of Biosimilar Manufacturer and Regulator Perceptions on Intellectual Property and Abbreviated Approval Pathways March 15, 2026
Market Exclusivity and Changes in Competition and Prices Associated with the US Food and Drug Administration Unapproved Drug Initiative March 15, 2026
Beyond the High Prices of Prescription Drugs: A Framework to Assess Costs, Resource Allocation, and Public Funding March 15, 2026